Corbus Pharmaceuticals (3371) Ratios
Corbus Pharmaceuticals Ratios
DE:3371's free cash flow for Q2 2026 was $-29.63M. For the 2026 fiscal year, DE:3371's free cash flow was decreased by $-6.00K and operating cash flow was $-29.63M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 |
| Quick Ratio | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 |
| Cash Ratio | 1.38 | 1.46 | 0.43 | 1.35 | 1.47 |
| Solvency Ratio | -3.78 | -2.94 | -1.25 | -1.63 | -1.14 |
| Operating Cash Flow Ratio | -3.12 | -3.54 | -1.13 | -2.97 | -2.83 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -2.23 | -11.92 | -12.48 |
| Net Current Asset Value | $ 146.26M | $ 139.53M | $ -11.63M | $ 26.86M | $ 61.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.74 | 0.38 | 0.25 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | -3.02 | 0.76 | 0.38 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 1.49 | 0.43 | 0.28 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.33 | 0.18 |
| Financial Leverage Ratio | 1.14 | 1.09 | -4.09 | 2.01 | 1.56 |
| Debt Service Coverage Ratio | 0.00 | -20.16 | -2.10 | -7.33 | -9.55 |
| Interest Coverage Ratio | 0.00 | -26.03 | -15.42 | -16.34 | -30.59 |
| Debt to Market Cap | 0.00 | 0.00 | 0.62 | 1.38 | 0.26 |
| Interest Debt Per Share | 0.12 | 0.47 | 5.50 | 6.53 | 6.93 |
| Net Debt to EBITDA | 0.34 | 0.37 | -0.18 | -0.21 | -0.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -85.92% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -6350.09% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -6164.17% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -6350.09% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -5176.38% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -5166.42% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -5176.38% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 131.85% | 99.81% |
| EBT Per EBIT | 92.06% | 82.53% | 98.95% | 121.56% | 81.52% |
| Return on Assets (ROA) | -46.69% | -25.80% | -157.77% | -84.20% | -42.28% |
| Return on Equity (ROE) | -53.24% | -28.23% | 645.97% | -169.24% | -65.92% |
| Return on Capital Employed (ROCE) | -57.84% | -33.82% | 1244.56% | -64.90% | -61.71% |
| Return on Invested Capital (ROIC) | -57.20% | -33.45% | -321.43% | -59.96% | -58.49% |
| Return on Tangible Assets | -46.69% | -25.80% | -157.77% | -84.20% | -42.28% |
| Earnings Yield | -72.45% | -31.22% | -170.67% | -402.01% | -60.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.13 | 0.00 | 0.68 | 0.92 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash Conversion Cycle | 0.00 | -2911.48 | 0.00 | -533.32 | -396.85 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2911.48 | 0.00 | 533.32 | 396.85 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.84 | -3.83 | -8.34 | -9.00 | -11.75 |
| Free Cash Flow Per Share | -4.84 | -3.83 | -8.34 | -9.01 | -11.77 |
| Dividend Paid and CapEx Coverage Ratio | -9213.00 | 0.00 | -12033491.00 | -2791.62 | -889.46 |
| Capital Expenditure Coverage Ratio | -9213.00 | 0.00 | -12033491.00 | -2791.62 | -889.46 |
| Operating Cash Flow Coverage Ratio | -39.49 | -12.90 | -1.73 | -1.50 | -1.81 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -54.65 |
| Free Cash Flow Yield | -59.50% | -32.45% | -138.13% | -270.42% | -63.67% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.38 | -3.20 | -0.59 | -0.25 | -1.66 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 85.93 |
| Price-to-Book (P/B) Ratio | 0.73 | 0.90 | -3.78 | 0.42 | 1.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.68 | -3.08 | -0.72 | -0.37 | -1.57 |
| Price-to-Operating Cash Flow Ratio | -1.68 | -3.08 | -0.72 | -0.37 | -1.57 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.05 | -0.37 | 0.03 | 0.02 |
| Enterprise Value Multiple | -1.04 | -3.04 | -0.83 | -0.57 | -1.42 |
| Enterprise Value | 81.54M | 114.84M | 33.30M | 21.98M | 77.35M |
| EV to EBITDA | -1.04 | -3.04 | -0.83 | -0.57 | -1.42 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 87.72 |
| EV to Free Cash Flow | -1.26 | -2.75 | -0.92 | -0.59 | -1.60 |
| EV to Operating Cash Flow | -1.26 | -2.75 | -0.92 | -0.59 | -1.61 |
| Tangible Book Value Per Share | 11.08 | 13.05 | -1.60 | 7.91 | 16.86 |
| Shareholders’ Equity Per Share | 11.08 | 13.05 | -1.60 | 7.91 | 16.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 |
| Net Income Per Share | -5.90 | -3.68 | -10.31 | -13.39 | -11.11 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.32 | 1.00 |
| Interest Burden | 1.00 | 1.05 | 1.09 | 1.05 | 0.82 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 41.34 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 23.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 10.75 |
| Income Quality | 0.82 | 1.04 | 0.81 | 0.89 | 1.06 |
Currency in USD